Organogenesis Holdings Inc NASDAQ:ORGO:

  • ANNOUNCES FDA ACCEPTANCE OF BIOLOGICS LICENSE APPLICATION FOR RENU® FOR THE MANAGEMENT OF SYMPTOMATIC KNEE OSTEOARTHRITIS

  • FDA SETS PDUFA TARGET ACTION DATE OF APRIL 24, 2027 FOR RENU BLA